Provided by Tiger Trade Technology Pte. Ltd.

Nutriband Inc.

4.67
+0.851422.32%
Post-market: 4.670.0036+0.08%19:57 EDT
Volume:67.53K
Turnover:294.66K
Market Cap:56.81M
PE:-1.86
High:4.75
Open:3.88
Low:3.87
Close:3.82
52wk High:8.63
52wk Low:2.80
Shares:12.17M
Float Shares:5.42M
Volume Ratio:7.84
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5150
EPS(LYR):-2.5809
ROE:-145.72%
ROA:-78.18%
PB:9.49
PE(LYR):-1.81

Loading ...

Company Profile

Company Name:
Nutriband Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
- -
Office Location:
121 South Orange Avenue,Suite 1500,Orlando,Florida,United States
Zip Code:
32801
Fax:
- -
Introduction:
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Directors

Name
Position
Gareth Sheridan
Chief Executive Officer and Director
Serguei Melnik
Chairman of the Board and Director and President and Secretary
Alessandro Puddu
Independent Director
Irina Gram
Independent Director
Mark Hamilton
Independent Director
Radu Bujoreanu
Independent Director
Sergei Glinka
Independent Director
Stefani Mancas
Independent Director
Viorica Carlig
Independent Director

Shareholders

Name
Position
Gareth Sheridan
Chief Executive Officer and Director
Alan Smith
Chief Operating Officer and President of 4P Therapeutics
Gerald Goodman
Chief Accounting Officer and Chief Financial Officer
Jeff Patrick
Chief Scientific Officer
Serguei Melnik
Chairman of the Board and Director and President and Secretary